GlobeNewswire

Shyft Unveils Board of Advisors Comprised of Top Crypto, Industry, and Regulatory Leaders United to Redefine Identity, Regulatory Compliance and Privacy For All

Dela

St. Michael, Barbados, June 21, 2018 (GLOBE NEWSWIRE) -- Shyft, a leading blockchain-based solution that is building a trusted ecosystem to enable secure and private data transfers, has announced its high profile Board of Advisors. Shyft's inaugural group of advisors bring deep industry knowledge from international business and finance, blockchain, economics, and Know Your Customer (KYC) and Anti Money Laundering (AML) compliance. The Board of Advisors will play a critical role in providing strategic guidance across multiple dimensions in Shyft's mission to make the global economy more efficient and effectively regulated.

 

Shyft International Chairman Joseph Weinberg says: "At Shyft, we are ambitiously working to redefine the broken way our world uses and thinks about data, the same data that today defines our identity. Our group of advisors understand the dire need for a new system that allows attested data to not only be shared securely and privately, but also a system that can help build reputational identity from this data that can be used globally across borders. This type of identity based on trustworthiness and credibility helps build a global economy that empowers the 3.5 billion people that are currently 'underidentified' and 'unbanked,' meaning that they are unable to participate in regulatory economies. Our caliber of advisors is second to none in the industry, which a testament to the enormity of the problem and to Shyft as the solution."

 

Shyft's advisors have diverse backgrounds, experiences and broad networks, and can individually and collectively provide unique perspective and strategic direction on the global and complex topic of identity, compliance and privacy, and how a disruptive technology like blockchain can solve a global problem. The advisors were carefully selected to include experts in finance, business, regulation, data privacy, and compliance and AML expertise. The Shyft Board of Advisors includes:

 

  • Joseph Weinberg - Shyft Chairman; Paycase CEO; Think Tank Specialist to the OECD
  • Meltem Demirors - Chief Strategy Officer, CoinShares; Member of Global Future Council on Blockchain, World Economic Forum
  • Daniel Kornitzer - EVP and Chief Business Development Officer, Paysafe Group
  • Anthony Di Iorio - CEO & Founder, Decentral and Jaxx; Ethereum Co-founder
  • Brock Pierce - Chairman, Bitcoin Foundation
  • Charlie Schrem - Founder,  Bitcoin Foundation and Crypto.IQ
  • Ben Gorlick - Investor; Chief of Strategy, Paycase; Founder / COO CLoudHashing; CTO CrowdMachine, Blockstream, Peer Nova
  • Marat Kichikov - Managing Partner,  CaBitfurypital
  • Peter Warrack - Chief Compliance Officer, Bitfinex; Director, AML Advisory and Compliance Officer at Bank of Montreal
  • Jeremy Bornstein - SVP and Group Head, Mastercard Canada
  • Diego Gutiérrez Zaldívar - CEO and Cofounder, RSK labs; President and Cofounder, Koibanx
  • Desmond McKenzie - Blockchain & Ecosystem Expert, Tata Consultancy Services
  • Lord Meghnad Desai - Noted Economist; Lord Speaker in the British House of Lords
  • Lord Anthony St John - Expert on Foreign Affairs and Clean Technology; Member of British House of Lords
  • Loretta Joseph - OECD Think Tank Advisor; Australian Digital Chamber of Commerce Chair
  • Dr. Jane Thomason - CEO, Blockchain Quantum Impact
  • Eyal Herzog - Product Architect, Bancor

 

Meltem Demirors shares: "Shyft is addressing one of the most challenging issues in our financial system - connecting identity and reputation to legacy financial products and emerging blockchain based financial services."

 

Anthony Di Iorio says: "Blockchain and the decentralized economy is about empowering individuals to take control of their digital lives. Today, most institutions hold centralized databases vulnerable to cyberattacks and the masses don't have control. When I learned of Shyft's vision to remove borders around personal identity using blockchain, I realized the full influence they will have on the whole global economy and the way we think about digital identity. To me, that is exciting."

 

Lord Anthony St. John concludes: "Having spent almost 25 years in the financial services in London, I see on a daily basis how KYC and proper due diligence are of pivotal importance. I also proudly serve on the House of Lords Ad Hoc Select Committee on Artificial Intelligence and am a member of the Parliamentary IT Committee. I am lucky to have a seat the intersection of finance and regulation and appreciate that compliance and due diligence are instrumental to the success of any business. However, KYC procedures are often cumbersome, time-consuming and inefficient. Shyft is unique in that it will deliver a trustworthy, resilient, expeditious, cost-effective and accredited platform."

 

In efforts to build and connect the many ecosystems that deal with data and identity today, Shyft will be featuring individual dialogue and commentary from its advisors through its various channels starting in early July. Learn more and connect with Shyft at shyft.network

 

###

 

Shyft Chairman Joseph Weinberg and CEO Bruce Silcoff are available for interview


About Shyft 
Shyft is building the world's first modern, secure, multi-stakeholder Blockchain-based digital identity ecosystem that enables KYC/AML attested data transfers. Combining privacy of data with efficiency of attestation, Shyft technology will radically streamline and simplify data collection, reduce cost and minimize the cybersecurity risks inherent in traditional compliance systems.  In addition, Shyft is working to make the global economy accessible for all by creating credible reputations for the 3.5 billion consumers who are lacking "identities" by today's standards. Through participation in the Shyft ecosystem, Shyft is building a more financially-inclusive future for everyone. If you are interested in working with Shyft and integrating your solution with our platform, please get in touch through contact@shyft.network. For more information on Shyft, please visit www.shyft.network.

Gaby Hui
Wachsman
9176021681
gaby@wachsman.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shyft Network via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum